ScinoPharm Taiwan Ltd
TWSE:1789
ScinoPharm Taiwan Ltd
Long-Term Debt
ScinoPharm Taiwan Ltd
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Long-Term Debt
NT$620.3m
|
CAGR 3-Years
5%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Long-Term Debt
NT$437.6m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
8%
|
CAGR 10-Years
12%
|
|
|
Formosa Laboratories Inc
TWSE:4746
|
Long-Term Debt
NT$2.8B
|
CAGR 3-Years
13%
|
CAGR 5-Years
2%
|
CAGR 10-Years
9%
|
|
|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Long-Term Debt
NT$584.4m
|
CAGR 3-Years
908%
|
CAGR 5-Years
245%
|
CAGR 10-Years
0%
|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Long-Term Debt
NT$8.6B
|
CAGR 3-Years
22%
|
CAGR 5-Years
17%
|
CAGR 10-Years
9%
|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Long-Term Debt
NT$367.6m
|
CAGR 3-Years
8%
|
CAGR 5-Years
21%
|
CAGR 10-Years
7%
|
|
ScinoPharm Taiwan Ltd
Glance View
ScinoPharm Taiwan Ltd. engages in the research, development, manufacturing, and sales of active pharmaceutical ingredients and injections. The company is headquartered in Tainan, Tainan. The company went IPO on 2010-10-29. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The firm is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The firm operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.
See Also
What is ScinoPharm Taiwan Ltd's Long-Term Debt?
Long-Term Debt
620.3m
TWD
Based on the financial report for Dec 31, 2024, ScinoPharm Taiwan Ltd's Long-Term Debt amounts to 620.3m TWD.
What is ScinoPharm Taiwan Ltd's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
1%
Over the last year, the Long-Term Debt growth was 9%. The average annual Long-Term Debt growth rates for ScinoPharm Taiwan Ltd have been 5% over the past three years , 1% over the past five years .
You don't have any saved screeners yet